Eli Lilly
NYSE:LLYPharmaIndianapolis, IN, United States · Est. 1875 · 43,000 employees
Global healthcare leader creating medicines that make life better.
76
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
80
Indications↗
Distinct diseases across all programs
2,323
Clinical Trials↗
All sponsored trials (all statuses)
51
Orange Book Patents
Across 9 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
76 drugs in development
Approved2
Phase 314
Phase 225
Phase 145
Preclinical6
By Therapeutic Area
top 6
Oncology
2931%
Metabolic & Endocrine
1415%
Neurology
1112%
Immunology
88%
Cardiovascular
44%
Musculoskeletal
44%
R&D Momentum
100/100
Pipeline Velocity
89/100
Trial Completion Rate
92/100
Pipeline Concentration
17/100
Pipeline Freshness
74/100
Strategic Signals
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 19, 2026
Active, not recruiting
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Sep 19, 2026
Active, not recruiting
A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and Tolerability of Two Formulations of Eltrekibart in Healthy Participants
Sep 19, 2026
Active, not recruiting
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of LY3867070 in Healthy Participants
Sep 19, 2026
Active, not recruiting
A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Sep 18, 2026
Recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-C
Sep 18, 2026
Recruiting
A Phase 1, Open-Label Study of LY5830966, a Type II JAK2 Inhibitor, in Patients With Myelofibrosis Previously Treated With a Type I JAK2 Inhibitor, JAK2 Inhibitor-Naïve Myelofibrosis, or High-risk Relapsed/Refractory Polycythemia Vera
Sep 18, 2026
Recruiting
A Master Protocol for Randomized, Placebo-Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Chronic Pain
Sep 18, 2026
Recruiting
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-D
Sep 16, 2026
Completed
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)
Sep 16, 2026
Completed
Impact of Variations in Urinary pH on the Pharmacokinetics of LY2140023 and LY404039 in Healthy Subjects
Details
Company Info
Company Overview
$750.0B
Mkt Cap
$34.1B
Revenue
$3.6B
Cash
CEODavid Ricks
Founded1875
Employees43,000
HQIndianapolis, IN, United States
ExchangeNYSE:LLY
Websitelilly.com
LinkedInCompany Page
Therapeutic Focus
Metabolic & EndocrineOncologyImmunologyCardiovascularOtherDermatologyNephrologyPsychiatryNeurologyHematologyMusculoskeletalInfectious DiseaseRare DiseaseGastroenterologyOphthalmologyRespiratory
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(4 drugs)
—
1
—
3
—
Cardiovascular(4 drugs)
Dermatology(1 drug)
—
—
—
1
—
Dermatology(1 drug)
Gastroenterology(2 drugs)
—
—
1
—
1
Gastroenterology(2 drugs)
Immunology(8 drugs)
1
2
3
2
1
Immunology(8 drugs)
Metabolic & Endocrine(14 drugs)
2
7
4
3
1
Metabolic & Endocrine(14 drugs)
Musculoskeletal(4 drugs)
—
—
4
—
—
Musculoskeletal(4 drugs)
Nephrology(2 drugs)
—
2
—
—
—
Nephrology(2 drugs)
Neurology(11 drugs)
2
4
4
1
—
Neurology(11 drugs)
Oncology(29 drugs)
1
22
6
3
—
Oncology(29 drugs)
Psychiatry(2 drugs)
—
—
1
2
—
Psychiatry(2 drugs)
Respiratory(1 drug)
—
—
1
—
—
Respiratory(1 drug)
Unknown / Other(17 drugs)
—
12
5
2
1
Unknown / Other(17 drugs)
Regulatory
Regulatory Timeline
202512 events
FDADec 2
Jaypirca — JAYPIRCA
Application NDA216059
FDANov 20
Retevmo — RETEVMO
Application NDA218160
FDANov 20
Retevmo — RETEVMO
Application NDA218160
FDANov 20
Retevmo — RETEVMO
Application NDA213246
FDANov 20
Retevmo — RETEVMO
Application NDA213246
FDAOct 28
EBGLYSS — EBGLYSS
Application BLA761306
FDAOct 23
Omvoh — OMVOH
Application BLA761279
FDASep 25
Inluriyo — INLURIYO
Application NDA218881 (NDA)
FDAJul 1
Kisunla — KISUNLA
Application BLA761248
FDAMay 22
EBGLYSS — EBGLYSS
Application BLA761306
FDAMar 21
Emgality — EMGALITY
Application BLA761063
FDAFeb 27
Verzenio — VERZENIO
Application NDA208716
20268 events
FDAJul 14
Retevmo — RETEVMO
Application NDA218160
FDAJul 14
Retevmo — RETEVMO
Application NDA213246
FDAJul 13
Verzenio — VERZENIO
Application NDA208716
FDAJun 30
Olumiant — OLUMIANT
Application NDA207924
FDAJun 9
EBGLYSS — EBGLYSS
Application BLA761306
FDAJun 5
Emgality — EMGALITY
Application BLA761063
FDAApr 1
Foundayo — FOUNDAYO
Application NDA220934 (NDA)
FDAJan 26
Folvite — QUIOFIC
Application NDA216395 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)